Dongwen Wu | Immunology | Best Researcher Award

Assoc. Prof. Dr. Dongwen Wu | Immunology | Best Researcher Award

Associate Professor at Central South University, China

Dr. Dongwen Wu has made impactful contributions in the fields of immunology and gastroenterology, with a total of 30 peer-reviewed publications, including 9 as first or corresponding author. His research has been cited 479 times, earning him an h-index of 12 and an i10-index of 14. His work has appeared in top-tier journals such as Nature Immunology, Science Immunology, and Journal of Experimental Medicine, and has been cited in Nature Reviews Immunology, Science, and Immunity. Dr. Wu’s research focuses on immune cell regulation, mucosal immunity, and the metabolic reprogramming of stromal and immune cells, with applications in inflammation, autoimmunity, and gastrointestinal disorders.

Publication Profile

Google Scholar

Educational Background 

  1. Doctor of Medicine (M.D.)

    • Focus: Clinical Medicine

  2. Doctor of Philosophy (Ph.D.)

    • Institution: Cornell University, Ithaca, NY, USA

    • Field: Likely Immunology or Biomedical Sciences, inferred from research focus and departmental affiliations.

    • Research Focus: Cytokine biology, Th17 cells, mucosal immunity, IL-17 signaling, immune system memory, and fibroblastic reticular cells.

Professional Experience 

  • 2024–2025 – Academic Evaluator, BIOMS 6250, Cornell University

  • 2025–2027 – Appointed Peer Reviewer, International Journal of Gastroenterology (1 of 18 reviewers selected)

  • 2023 – Peer Reviewer, Scientific Reports (PMID: 37635176)

  • 2023 – Peer Reviewer, BMC Cancer (PMID: 37507682)

Dr. Wu has demonstrated leadership and recognition in his field through academic teaching and active peer-review service for internationally recognized journals.

Research Interests 

  • IL-17 signaling and fibroblastic reticular cell (FRC) biology

  • Mucosal immunity and stromal cell–immune cell interactions

  • Metabolic reprogramming in immune and stromal cells

  • Pathogenic Th17 cell function and noncanonical STAT3 activity

  • Dietary impact on immune training and gut inflammation

  • Immunological biomarkers in inflammatory bowel disease (IBD) and cancer

Professional Memberships

  • Member, International Cytokine and Interferon Society (ICIS)

  • Member, American Association of Immunologists (AAI)

  • Member, Youth Scientific Research Club, IBD Committee, Chinese Society of Gastroenterology

Conclusion 

Dr. Dongwen Wu is a distinguished physician-scientist whose multidisciplinary work bridges immunology, gastroenterology, and metabolic research. With high-impact publications and ongoing roles in academic evaluation and peer review, Dr. Wu has established himself as a valuable contributor to the biomedical research community. His insights into stromal–immune interactions and immune training by diet represent novel directions in inflammation and mucosal immunology.

Publications 

  • Wu, D.W., Wang, X., Yang, X., Gu, L., McGeachy, M.J., & Liu, X. (2023).
    Temporary consumption of western diet trains the immune system to reduce future gut inflammation.
    iScience, 26(6), 106915. PMID: 37305694


  • Zhou, J., Cai, T., Wu, D.W., Chen, X., & Wang, F. (2023).
    The role of endoscopic ultrasound-guided fine-needle aspiration/biopsy in the diagnosis of mediastinal lesions.
    Frontiers in Surgery, 9, 1065070. PMID: 36684177


  • Wu, D.W., Poholek, C.H., Majumder, S., Liu, Q., Revu, S.K., Mohib, K., … & McGeachy, M.J. (2021).
    IL-17–dependent fibroblastic reticular cell training boosts tissue protective mucosal immunity through IL-10–producing B cells.
    Science Immunology, 6(66), eaao3669. PMID: 34919443


  • Xiao, Y.#, Wu, D.W.#, Shi, X.#, Liu, S.#, Hu, X., Zhou, C., … & Chen, M. (2021).
    High Child-Pugh and CRUB65 scores predict mortality of decompensated cirrhosis patients with COVID-19: A 23-center, retrospective study.
    Virulence, 12(1), 1199–1208. PMID: 33870852


  • Zhou, C., Wu, D.W., Jawale, C., Li, Y., Biswas, P.S., McGeachy, M.J., & Gaffen, S.L. (2021).
    Divergent functions of IL-17-family cytokines in DSS colitis: Insights from a naturally-occurring human mutation in IL-17F.
    Cytokine, 148, 155715. PMID: 34587561


  • Poholek, C.H., Raphael, I., Wu, D.W., Revu, S., Rittenhouse, N., Uche, U.U., … & McGeachy, M.J. (2020).
    Noncanonical STAT3 activity sustains pathogenic Th17 proliferation and cytokine response to antigen.
    Journal of Experimental Medicine, 217(10). PMID: 32697822


  • Xiao, Y., Shi, X., She, Q., Chen, Q., Pan, H., Zhang, J., Liu, X.J., Wu, H.Y., Jin, W.F., Ke, G., Liu, S.Z., Li, J., Zhou, J., Wu, D.W., … & Chen, M. (2020).
    Exploration of turn-positive RT-PCR results and factors related to treatment outcome in COVID-19: A retrospective cohort study.
    Virulence, 11(1), 1250–1256. PMID: 32921249


  • Majumder, S., Amatya, N., Revu, S., Jawale, C.V., Wu, D.W., Rittenhouse, N., … & McGeachy, M.J. (2019).
    IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival.
    Nature Immunology, 20(5), 534–545. PMID: 30962593


  • Lin, J., Tan, H., Nie, Y., Wu, D.W., Zheng, W., Lin, W., … & Chen, T. (2019).
    Krüppel‐like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway.
    Cancer Science, 110(4), 1220–1231. PMID: 30719823


  • Deng, G., Li, H., Zeng, F., Chen, L., Li, H., Wu, D.W., … & Wang, Z. (2019).
    Pringle maneuver versus hemihepatic blood flow occlusion during hepatectomy: a systematic review and meta-analysis.
    International Journal of Clinical and Experimental Medicine, 12(1), 11–25.


  • Zhang, K., Tian, J., He, Z., Sun, W., Pekbay, B., Lin, Y., Wu, W.D., … & Zhang, L. (2018).
    Validation of the Chinese version of EORTC QLQ‐BN 20 for patients with brain cancer.
    European Journal of Cancer Care, 27(2), e12832. PMID: 29461664


  • Wu, D.W.* Li, Y., & Wang, F. (2017).
    How long can we store blood samples: a systematic review and meta-analysis.
    EBioMedicine, 24, 277–285. PMID: 28965875


  • Li, H.#, Wu, D.W.#, Shi, S., Xu, Y., Wei, L., Liu, J., & Liu, Y. (2017).
    Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis.
    Oncotarget, 8(31), 51331. PMID: 28881651


  • Li, H.#, Jiang, C.#, Wu, D.W.#, Shi, S., Liao, M., Wang, J., … & Xu, Z. (2017).
    The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: A meta-analysis.
    PLoS ONE, 12(7), e0180271. PMID: 28700599


  • Zhang, Z.#, Zhang, X.#, Wei, L.#, Lin, Y.#, Wu, D.W.#, Xie, S., … & Zhang, L. (2017).
    Questionnaire to assess quality of life in patients with breast cancer – validation of the Chinese version of the EORTC QLQ-BR 53.
    The Breast, 32, 87–92. PMID: 28068605


 

 

 

 

Amr Radwan | Immunology | Best Researcher Award

Dr. Amr Radwan | Immunology | Best Researcher Award

Executive Medical Director at Regeneron, United Kingdom

Dr. Amr AH Radwan is a distinguished medical affairs leader with over two decades of global experience spanning clinical medicine, pharmaceutical medicine, immunology, gastroenterology, and strategic leadership in drug development and market access. Currently serving as Executive Medical Director at Regeneron Pharmaceuticals Inc., he brings deep scientific expertise and cross-functional insight to global medical affairs, particularly in immunological disorders and biologics. His work bridges the interface of clinical innovation, medical strategy, regulatory frameworks, and international healthcare markets.

Publication Profile 

Orcid

Educational Background 🎓

  • University of Cambridge

    • MB BChir (Bachelor of Medicine and Surgery), 1998

    • BA in Pathology (Honours), 1996

    • MA (Cantab), 1999

  • Royal College of Surgeons (Edinburgh)

    • AFRCS Part 1 (MCQ I & II), 2001

  • The Berne Institute, Kegworth

    • Foundation Training in Transactional Analysis Counselling & Psychotherapy, 2003

  • University of Cardiff

    • Diploma in Pharmaceutical Medicine, 2010

  • Royal College of Physicians

    • Membership of Faculty of Pharmaceutical Medicine, 2011

    • Specialist Training in Pharmaceutical Medicine, 2011

    • Fellowship, 2016

Professional Experience 💼

🏢 Regeneron Pharmaceuticals Inc. (2018–Present)

  • Executive Medical Director, Global Medical Affairs (2022–Present)

  • Senior Director, Global Medical Affairs (2019–2021)

  • Senior Director, Medical Affairs EU (2018–2019)

    • Key leadership in global immunology franchise across dermatology, respiratory, and GI indications (e.g., Dupilumab, Itepekimab).

    • Led GI franchise (EoE, EoG, eUC) strategy and ex-US medical organization restructuring.

    • Partnered with commercial, legal, and R&D teams for European, Canadian, and Japanese market expansions.

🏢 Aimmune Therapeutics Ltd. (2016–2018)

  • Vice President, Medical Affairs & Market Access

    • EU and global leadership for peanut allergy therapy; directed Drug Safety & PV, Market Access, and clinical trial governance.

🏢 Norgine Pharmaceuticals UK Ltd. (2014–2016)

  • Medical Director – EU

    • Led EU medical affairs, market access, PV, and NICE submission strategies; managed 8 country-level medical teams; oversaw clinical trials and licensing responses.

Research Interests 🔬

  • Pharmaceutical Medicine & Clinical Drug Development

  • Immunology, Dermatology, and Gastroenterology (e.g., EoE, PN, CRSwNP)

  • Allergic Disorders and Biologics (e.g., anti-IL33, anti-Fel D1)

  • Regulatory Compliance, Pharmacovigilance & Risk Management

  • Clinical Strategy and Market Access Studies

Awards and Honors🏆✨

  • Queens’ College Exhibition Prize (1994–1996)
    Awarded for First Class academic performance in Preclinical Sciences.

  • Fawcett Memorial Prize (1998)
    Recognized for Outstanding Communication Skills.

  • Fellowship of the Faculty of Pharmaceutical Medicine (2016)
    Awarded by Royal College of Physicians for significant contributions to Pharmaceutical Medicine.

Additional Credentials & Interests

  • Languages & Communication: Fluent in Arabic, English, and French.

  • Advanced Certifications:

    • IAM-trained motorcyclist (Institute of Advanced Motorists)

    • PADI Advanced & BSAC Sports Scuba Diving certifications

  • Hobbies:

    • Partner dancing (Argentine Tango, Blues, Modern Jive)

    • Literature, philosophy, and motorcycling

Conclusion🌟

Dr. Amr AH Radwan is a highly accomplished physician-leader whose contributions have shaped global medical affairs practices, especially in immunology and allergy-based therapeutics. His unique blend of clinical training, regulatory expertise, and cross-continental leadership makes him a significant figure in modern pharmaceutical medicine and translational healthcare strategy. He is well-suited for high-level recognition, awards, and continued leadership in both academic and industry circles.

Publications 📚

  1. 📄 A Real-World Study of Cumulative Steroid Burden Among Patients with Eosinophilic Esophagitis in the United States
    📰 Clinical Gastroenterology and Hepatology (Mar 2025)
    🔗 DOI: 10.1016/j.cgh.2025.01.010


  1. 📄 Baseline Disease Characteristics by Surgery History Among Patients with CRSwNP: AROMA Registry
    📰 American Journal of Otolaryngology (Mar 2025)
    🔗 DOI: 10.1016/j.amjoto.2024.104596


  1. 📄 Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: VOYAGE (Post Hoc)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Mar 2025)
    🔗 DOI: 10.1016/j.jaip.2024.11.014


  1. 📄 Burden of Eosinophilic Esophagitis in Adults and Adolescents: Real-World Analysis
    📰 Diseases of the Esophagus (Mar 3, 2025)
    🔗 DOI: 10.1093/dote/doaf024


  1. 📄 Dupilumab Efficacy in EoE Irrespective of Prior Swallowed Corticosteroids: LIBERTY EoE TREET Trial
    📰 Expert Review of Gastroenterology & Hepatology (Feb 2025)
    🔗 DOI: 10.1080/17474124.2025.2461516


  1. 📄 Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Therapy Response
    📰 American Journal of Respiratory and Critical Care Medicine (Feb 12, 2025)
    🔗 DOI: 10.1164/rccm.202407-1379ci


  1. 📄 Dupilumab Induces Long-Term On-Treatment Clinical Remission in Type 2 Asthma
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Jan 2025)
    🔗 DOI: 10.1016/j.jaip.2024.10.009


  1. 📄 Disease Burden and Symptoms Impacting Quality of Life in Pediatric EoE Patients
    📰 Gastro Hep Advances (2024)
    🔗 DOI: 10.1016/j.gastha.2024.08.009


  1. 📄 Real-World Characteristics of Severe Asthma Patients Before Dupilumab: ProVENT Study
    📰 Respiration (2024)
    🔗 DOI: 10.1159/000535390


  1. 📄 Dupilumab Efficacy in Children With Type 2 Asthma on High-/Medium-Dose ICS (VOYAGE)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Dec 2024)
    🔗 DOI: 10.1016/j.jaip.2024.08.038